Watch BTCY. Know when insiders buy.
One email the day a filing lands. Free.
BTCY
BIOTRICITY INC.
0.05
+0.00 +10.00%
USD · close Oct 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1MP/E —DIV YIELD —FCF YIELD —REV TTM $16.4M +13.4%NET INCOME −$2.7MNET CASH —52W 0.04 – 0.65SEC XBRL · TTM TO Invalid Date
How BTCY rewrote its risk factors
Text kept
98%
of sentences unchanged
Added
5
new sentences
Dropped
5
sentences removed
Length
+1
words, now 12,458
New in FY2026
- As of March 31, 2026, we had an accumulated deficit of $142,570,243.
- As of March 31, 2026, in addition to our accounts payable, we had aggregate outstanding indebtedness of $26.7 million compared to $25.2 million for the year ended March 31, 2025.
- As of March 31, 2026, the Company had $149,789 in cash, accumulated deficit of $142,570,243 and cash flow used in operations of $ 720,955 for the fiscal year then ended.
- We have 29,402,934 outstanding shares as of June 20, 2026, of which 13,940,360 are unrestricted shares of common stock, such that a large number of shares of our common stock could be made available for sale in the public market, which could harm the market price of the stock.
- Our management has concluded that our internal controls over financial reporting were, and continue to be, effective, as of March 31, 2026.
Gone since FY2025
- As of March 31, 2025, we had an accumulated deficit of $138,895,913.
- As of March 31, 2025, in addition to our accounts payable, we had aggregate outstanding indebtedness of $25.2 million compared to $22.6 million for the year ended March 31, 2024.
- As of March 31, 2025, the Company had $365,145 in cash, accumulated deficit of $138,972,413 and cash flow used in operations of $2,312,834 for the fiscal year then ended.
- We have 26,567,769 outstanding shares as of July 15, 2025, of which 12,325,165 are unrestricted shares of common stock, such that a large number of shares of our common stock could be made available for sale in the public market, which could harm the market price of the stock.
- Our management has concluded that our internal controls over financial reporting were, and continue to be, effective, as of March 31, 2025.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2025 ↗, FY2026 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.